Target | Positive in PHC | Positive in DCC | SN | SP | LR (+) (95% CI) | LR (−)(95% CI) | P-value |
---|---|---|---|---|---|---|---|
Single marker for PHC diagnosis | |||||||
 KRT17 | 55/72 | 21/74 | 76.4% | 71.6% | 2.69 (2.50–2.90) | 0.330 (0.299–0.364) | 0.0001 |
 ANXA10 | 59/72 | 36/74 | 81.9% | 51.3% | 1.68 (1.63–1.72) | 0.352 (0.303–0.408) | 0.0001 |
 TMEM109 | 48/72 | 27/74 | 66.7% | 63.5% | 1.82 (1.72–1.94) | 0.525 (0.490–0.563) | 0.0003 |
Single marker for DCC diagnosis | |||||||
 PTMS | 20/72 | 45/74 | 60.8% | 72.2% | 2.19 (2.04–2.35) | 0.543 (0.520–0.566) | 0.0001 |
 ATP1B1 | 30/72 | 45/74 | 60.8% | 58.3% | 1.45 (1.39–1.54) | 0.672 (0.635–0.711) | 0.031 |
Panel for PHC diagnosis | |||||||
 KRT17+/ANXA10+/PTMS- | 34/72 | 6/74 | 47.2% | 91.9% | 5.82 (4.18–8.11) | 0.574 (0.559–0.590) | 0.0001 |
Panel for DCC diagnosis | |||||||
 KRT17−/ANXA10−/PTMS+ | 2/72 | 17/74 | 23.0% | 97.2% | 8.27 (3.46–19.7) | 0.792 (0.786–0.798) | 0.0003 |